These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35577731)

  • 1. Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.
    Castel-Ajgal Z; Goulvestre C; Zaibet S; Arrondeau J; Bretagne M; Peyromaure M; Batteux F; Alexandre J; Goldwasser F; Huillard O
    Clin Genitourin Cancer; 2022 Oct; 20(5):e362-e368. PubMed ID: 35577731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
    Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
    Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
    Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Katayama S; Iwata T; Kawada T; Okamoto Y; Sano Y; Kawago Y; Miyake S; Moriwake T; Kuinose A; Horikawa Y; Tsuboi K; Tsuboi I; Sakaeda K; Nakatsuka H; Takamoto A; Hirata T; Shirasaki Y; Yamasaki T; Morinaka H; Nagasaki N; Hara T; Ochi A; Okumura M; Watanabe T; Sekito T; Kawano K; Horii S; Yamanoi T; Nagao K; Yoshinaga K; Maruyama Y; Tominaga Y; Sadahira T; Nishimura S; Edamura K; Kobayashi T; Kusumi N; Kurose K; Yamamoto Y; Sugimoto M; Nakada T; Sasaki K; Takenaka T; Ebara S; Miyaji Y; Wada K; Kobayashi Y; Araki M
    Urol Oncol; 2024 Mar; 42(3):70.e11-70.e18. PubMed ID: 38129282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
    Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
    Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
    Morimoto K; Yamada T; Nakamura R; Katayama Y; Tanaka S; Takumi C; Hiraoka N; Ogura Y; Takeda T; Onoi K; Chihara Y; Taniguchi R; Yamada T; Matsui Y; Hiranuma O; Morimoto Y; Iwasaku M; Kaneko Y; Uchino J; Takayama K
    Med Oncol; 2020 Nov; 37(12):111. PubMed ID: 33175248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.
    Hsu SJ; Chao YC; Lin XH; Liu HH; Zhang Y; Hong WF; Chen MP; Xu X; Zhang L; Ren ZG; Du SS; Chen RX
    Clin Exp Immunol; 2023 Jun; 212(3):239-248. PubMed ID: 36966354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
    Yoneshima Y; Tanaka K; Shiraishi Y; Hata K; Watanabe H; Harada T; Otsubo K; Iwama E; Inoue H; Masuda S; Nakanishi Y; Okamoto I
    Lung Cancer; 2019 Apr; 130():5-9. PubMed ID: 30885351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.
    Sakakida T; Ishikawa T; Chihara Y; Harita S; Uchino J; Tabuchi Y; Komori S; Asai J; Narukawa T; Arai A; Tsunezuka H; Kosuga T; Konishi H; Moriguchi M; Yasuda H; Hongo F; Inoue M; Hirano S; Ukimura O; Itoh Y; Taguchi T; Takayama K
    Clin Transl Oncol; 2020 Jun; 22(6):919-927. PubMed ID: 31576495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Sano T; Aizawa R; Ito K; Nakamura K; Ogata T; Takeda M; Hamada A; Matsuoka T; Kono J; Kita Y; Masui K; Goto T; Sawada A; Akamatsu S; Ogawa O; Mizowaki T; Kobayashi T
    Anticancer Res; 2023 May; 43(5):2119-2126. PubMed ID: 37097696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
    Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.